/f/125658/7246x3240/f72d1f6fc5/esc-logo-lock-up-red-pos-rgb.png){kind=logo}
/f/125658/5000x1496/8aa45c8224/eacvi-acronym-text-rgb.png)
Sarah Cuddy is a cardiologist at the Brigham and Women's Hospital and an Instructor at Harvard Medical School. She trained in Ireland prior to moving to Boston for specialist training in multi-modality imaging. Her research focus is the use of imaging in cardiac amyloidosis, particularly for early detection of disease and to track response to therapy. She has an early career grant to evaluate machine learning to detect cardiac amyloidosis with standard echocardiography. She is the site-PI for two large multi-center phase 3 trials of novel gene-silencers in transthyretin cardiac amyloidosis (ATTR) at the Brigham and Women's Hospital. She has published several reviews on cardiac amyloidosis, and original work on early changes in light chain amyloidosis detected with MRI and F18-florbetapir imaging. She has also published original work on incidental coronary calcium on lung cancer imaging and other uses of multi-modality cardiac imaging in diagnosis and prognosis.
